Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Fiore

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Eclinicalmedicine|May 9, 2020
A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in <i>Mycobacterium tuberculosis</i>-uninfected adolescents in Cape Town, South AfricaLinda-Gail Bekker, One Dintwe, Andrew Fiore-Gartland, et al.
Medrxiv : the Preprint Server for Health Sciences|December 17, 2020
Evaluation of SARS-CoV-2 neutralization assays for antibody monitoring in natural infection and vaccine trialsAnton M Sholukh, Andrew Fiore-Gartland, Emily S Ford, et al.
The Lancet. Respiratory Medicine|July 6, 2025
Evidence required to evaluate the use of bacteriologically confirmed asymptomatic tuberculosis disease as a primary endpoint in prevention of tuberculosis disease vaccine licensure trialsRichard G White, Gavin J Churchyard, Katherine C Horton, et al.
Immunohorizons|September 16, 2024
Probing Dermal Immunity to Mycobacteria through a Controlled Human Infection ModelE Chandler Church, Emma Bishop, Andrew Fiore-Gartland, et al.
Research Square|October 20, 2022
CD8<sup>+</sup> T cell clonotypes from prior SARS-CoV-2 infection predominate during the cellular immune response to mRNA vaccinationEmily S Ford, Koshlan Mayer-Blackwell, Lichen Jing, et al.
The Lancet. Infectious Diseases|January 28, 2021
Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trialThomas J Scriba, Andrew Fiore-Gartland, Adam Penn-Nicholson, et al.
The Lancet. Global Health|April 16, 2021
Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy studySimon C Mendelsohn, Andrew Fiore-Gartland, Adam Penn-Nicholson, et al.
The Lancet. Respiratory Medicine|December 11, 2020
Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trialTracey A Day, Adam Penn-Nicholson, Angelique Kany Kany Luabeya, et al.
Plos One|January 31, 2020
Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South AfricansLue Ping Zhao, Andrew Fiore-Gartland, Lindsay N Carpp, et al.
Nature Immunology|December 6, 2023
Repeated mRNA vaccination sequentially boosts SARS-CoV-2-specific CD8<sup>+</sup> T cells in persons with previous COVID-19Emily S Ford, Koshlan Mayer-Blackwell, Lichen Jing, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Eclinicalmedicine|May 9, 2020
A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in <i>Mycobacterium tuberculosis</i>-uninfected adolescents in Cape Town, South AfricaLinda-Gail Bekker, One Dintwe, Andrew Fiore-Gartland, et al.
Medrxiv : the Preprint Server for Health Sciences|December 17, 2020
Evaluation of SARS-CoV-2 neutralization assays for antibody monitoring in natural infection and vaccine trialsAnton M Sholukh, Andrew Fiore-Gartland, Emily S Ford, et al.
The Lancet. Respiratory Medicine|July 6, 2025
Evidence required to evaluate the use of bacteriologically confirmed asymptomatic tuberculosis disease as a primary endpoint in prevention of tuberculosis disease vaccine licensure trialsRichard G White, Gavin J Churchyard, Katherine C Horton, et al.
Immunohorizons|September 16, 2024
Probing Dermal Immunity to Mycobacteria through a Controlled Human Infection ModelE Chandler Church, Emma Bishop, Andrew Fiore-Gartland, et al.
Research Square|October 20, 2022
CD8<sup>+</sup> T cell clonotypes from prior SARS-CoV-2 infection predominate during the cellular immune response to mRNA vaccinationEmily S Ford, Koshlan Mayer-Blackwell, Lichen Jing, et al.
The Lancet. Infectious Diseases|January 28, 2021
Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trialThomas J Scriba, Andrew Fiore-Gartland, Adam Penn-Nicholson, et al.
The Lancet. Global Health|April 16, 2021
Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy studySimon C Mendelsohn, Andrew Fiore-Gartland, Adam Penn-Nicholson, et al.
The Lancet. Respiratory Medicine|December 11, 2020
Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trialTracey A Day, Adam Penn-Nicholson, Angelique Kany Kany Luabeya, et al.
Plos One|January 31, 2020
Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South AfricansLue Ping Zhao, Andrew Fiore-Gartland, Lindsay N Carpp, et al.
Nature Immunology|December 6, 2023
Repeated mRNA vaccination sequentially boosts SARS-CoV-2-specific CD8<sup>+</sup> T cells in persons with previous COVID-19Emily S Ford, Koshlan Mayer-Blackwell, Lichen Jing, et al.
Pageof 8